In today’s busy world, staying fit and energized can feel like a challenge. Many people are looking for natural ways t ...

Insomnia, characterized by difficulties in sleep onset and/or sleep maintenance, impacts both physical and mental health. The ...

Short sleepers cruise by on four to six hours a night and don’t seem to suffer ill effects. Turns out they’re genetically ...

Discover the truth behind OrexiBurn reviews —find out how this weight loss supplement transformed my results after just 30 ...

mezagitamab, an investigational anti-CD38 antibody providing rapid, selective and sustained depletion of disease-causing ...

NLS Pharmaceutics (NLSP) announced that its CEO Alex Zwyer, has issued a letter to shareholders, which read in part, “Over the past several ...

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the ...

Satisfied, the team named them “orexin-A” and “orexin-B,” for the Greek word “orexis,” meaning appetite. The brain receptors became “orexin-1” and “orexin-2.” The team prepared ...

NLS Pharmaceutics (NLSP) shared preclinical data demonstrating the potential of its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to ...

ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a ...

周三，Piper Sandler维持了对Alkermes（NASDAQ:ALKS）的"增持"评级，并重申了37美元的目标价。该公司的立场受到ALKS-2680潜力的影响，这是一种目前正在开发用于治疗睡眠/觉醒障碍的orexin 2受体（OX2R）激动剂。